Upload
lgaldieri
View
222
Download
0
Embed Size (px)
Citation preview
8/8/2019 Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and…
http://slidepdf.com/reader/full/histone-deacetylase-inhibitor-potentiates-anticancer-effect-of-docetaxel-via 1/8
Histone Deacetylase Inhibitor Potentiates Anticancer Effect ofDocetaxel via Modulation of Bcl-2 Family Proteins and Tubulin inHormone Refractory Prostate Cancer Cells
Jung Jin Hwang, Yong Sook Kim, Mi Joung Kim, Dong Eun Kim, In Gab Jeong
and Choung-Soo Kim*
From the Institute for Innovative Cancer Research (JJH, YSK, MJK, DEK) and Department of Urology (IGJ), University of Ulsan College of
Medicine, Asan Medical Center (CSK), Seoul, Korea
Purpose: We evaluated the antitumor effects of docetaxel (Sigma®) and histone
deacetylase inhibitors in hormone refractory prostate cancer cells, and analyzed
the mechanism by which combination treatment induced cell death.Materials and Methods: We used LNCaP, DU145 and PC3 cells (ATCC®) toevaluate the in vitro apoptotic effects of histone deacetylase inhibitors and their
combinations with docetaxel as well as the molecular mechanisms. The DU145xenograft model was used to evaluate the in vivo efficacy of PXD101 combined
with docetaxel.Results: Suberoylanilide hydroxamic acid or PXD101 inhibited the growth of
hormone dependent LNCaP cells, and hormone independent DU145 and PC3cells. It increased sub-G1 population and activated caspase-8, 9 and 3, indicating
apoptosis induction. Pretreating DU145 cells with docetaxel followed by histonedeacetylase inhibitors showed significant synergistic cytotoxicity compared with
that of simultaneous co-treatment or reverse sequential treatment. Pretreatment
with docetaxel followed by histone deacetylase inhibitors increased the apoptoticsub-G1 population, caspase activation and tubulin acetylation compared withthat of docetaxel alone. Combination treatment decreased Mcl-1 and Bcl-xl, and
increased t-Bid, Bik and Bim. Combined docetaxel and PXD101 reduced tumorsize with efficacy equivalent to that of a double dose of docetaxel alone in the
DU145 xenograft model.
Conclusions: These preclinical results indicate that the sequential combination
of docetaxel and histone deacetylase inhibitors led to a synergistic increase in the
death of hormone refractory prostate cancer cells via intrinsic and extrinsicapoptotic pathways by modulating Bcl-2 family proteins and tubulin in vitro and
in vivo. Results suggest that this combination may be a new therapeutic modalityin patients with hormone refractory prostate cancer.
Key Words: prostate, prostatic neoplasms, histone deacetylases,docetaxel, apoptosis
Abbreviations
and Acronyms
CI combination index
HDAC histone deacetylase
HDACI HDAC inhibitor
HRPC hormone refractory
prostate cancer
MTS 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium
SAHA suberoylanilide
hydroxamic acid
v/v volume per volume
Submitted for publication March 23, 2010.
Study received institutional animal care and
use committee approval.
Supported by Grant A062254 from the Korea
Health 21 R & D Project, Ministry of Health, Wel-
fare and Family Affairs, and a grant (2009-450)
from the Asan Institute for Life Sciences, Repub-
lic of Korea.
* Correspondence: Department of Urology,
Asan Medical Center, 388-1 Pungnap 2 dong,
Songpa-gu, Seoul 138-736, Korea (telephone: 82-2-
3010-3734; FAX: 82-2-477-8928; e-mail: cskim@
amc.seoul.kr).
PROSTATE cancer is the most common
nonskin cancer and the second most
common cause of cancer death in men
in the United States with an estimated
186,320 newly diagnosed patients and
27,360 prostate cancer deaths in 2008.1
Although docetaxel based regimens
have palliative and survival bene-
fits, men with metastatic HRPC
have only 16 to 18-month median
survival.2,3 Thus, new therapeutic
modalities aimed to improve man-
0022-5347/10/1846-2557/0 Vol. 184, 2557-2564, December 2010
THE JOURNAL OF UROLOGY® Printed in U.S.A.© 2010 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC. DOI:10.1016/j.juro.2010.07.035
www.jurology.com 2557
8/8/2019 Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and…
http://slidepdf.com/reader/full/histone-deacetylase-inhibitor-potentiates-anticancer-effect-of-docetaxel-via 2/8
agement for advanced HRPC include docetaxel
plus other agents.4
The importance of epigenetic changes in cancer
cells led to the development of agents that modify
histones via acetylation, methylation, phosphoryla-
tion, ubiquitination or adenosine triphosphate ribo-
sylation, or that methylate DNA. Of these modifica-tions the acetylation of lysine residues at the histone
N-terminal tail decreases the affinity of histone for
DNA, resulting in the expression of genes related to
tumor suppression and/or differentiation.5 Thus,
HDACIs show potent activity against many can-
cers.6 Five HDACI classes have been characterized,
including the hydroxamic acids SAHA, PXD101,
LAQ-824, LBH 589 and trichostatin A, the short-
chain fatty acids 4-phenylbutyrate, pivaloyloxy-
methyl butyrate and valproic acid, the cyclic tet-
rapeptides trapoxin, apicidin and depsipeptide (FK
228), and benzamide (MS-275).7–10 Many reportsshow the usefulness of various HDACIs for prostate
cancer.11
Cell death mechanisms of HDACIs include induc-
tion of the cyclin dependent kinase inhibitors p21
and p27, apoptotic Bcl-2 family proteins, death re-
ceptors, death ligands and retinoic acid receptor.8,12
HDACI also acetylates many nonhistone proteins,
including tubulin, heat shock proteins and Ku70,
disrupting protein function and resulting in cell
death.13–15 Although it was reported that SAHA,
valproic acid, MS-275, PXD101 and FR235222 de-
creased prostate specific antigen, and increasedcaspase activation, and p21 and annexin A1 expres-
sion in a prostate cancer cell line,11,16–19 the precise
mechanism of HDACIs must be further elucidated.
The merit of HDACIs is that cytotoxic effects are
specific to cancer cells and not to normal cells or
tissues. HDACIs are well tolerated with a good tox-
icity profile compared to that of other anticancer
agents.7 Many clinical trials have been done or are
under way using HDACIs combined with other che-
motherapy, for example the taxane paclitaxel or
docetaxel combined with the HDACI pivaloyloxy-
methyl butyrate, LBH589, SAHA or PXD101 forsolid tumors, including prostate, breast and lung
cancer.9,20–22 However, the exact mechanism of ac-
tion is not fully understood.
We determined whether HDACIs would enhance
the effects of docetaxel in advanced prostate cancer
cells. We also assessed the mechanism of cell death.
Thus, we evaluated the growth inhibitory effects of
HDACI alone in hormone dependent and indepen-
dent prostate cancer cells. Finally, we determined
the antitumor effect of docetaxel and HDACI in
HRPC DU145 cells in vitro and in vivo, and ana-
lyzed the mechanism by which combination treat-
ment induced cell death.
MATERIALS AND METHODS
Cell Culture and Drug TreatmentWe cultured the human prostate cancer cell lines LNCaP,
DU145 and PC3 in RPMI 1640 medium containing 100
U/ml penicillin, 100 g/ml streptomycin and 10% (v/v)
fetal bovine serum (Invitrogen™). The HDACIs SAHA
and PXD101 were synthesized elsewhere. We treated cellswith SAHA, PXD101 or docetaxel in 5% (v/v) RPMI 1640
medium containing fetal bovine serum. For sequential
combination treatment with HDACI and docetaxel cells
were exposed to the former drug for 24 hours and then to
the next drug for another 48 hours.
Cell Survival and CI AnalysisCells were cultured in 96-well plates and treated with
various drug concentrations for the indicated times. We
measured viability with the CellTiter 96® Aqueous One
Solution Cell proliferation assay (MTS assay). MTS re-
agent was added to each well according to manufacturer
instructions. After 2-hour incubation we determined cell viability by measuring absorbance at 490 nm.
We calculated the CI with CalcuSyn (Biosoft®), which
is based on the Chou and Talalay median effect principle.
The isobologram is a graphic representation of the inter-
action between 2 drugs that is formed by plotting the
individual drug doses required to achieve a single agent
effect on the respective x and y-axes. A line connecting the
2 points is drawn and the concentration of the 2 drugs
used in combination to achieve the same effect is plotted
on the isobologram. Combination data points that fall on
the line represent an additive interaction while points
above and below represent antagonism and synergy, re-
spectively. Similar to the isobologram, CI analysis pro- vides qualitative information on the drug interaction. A
numerical CI value is calculated based on the equation,
CI (D)1/(Dx)1 (D)2/(Dx)2 (D)1(D)2/(Dx)1(Dx)2,
where (D)1 and (D)2 are the doses of drugs 1 and 2 with a
certain percent effect when used in combination, and
(Dx)1 and (Dx)2 are the doses of drugs 1 and 2, respec-
tively, with the same certain percent effect when used
alone. CI greater than 1 indicates antagonism, 1 indicates
an additive effect and less than 1 indicates synergy.
Cell Cycle AnalysisCells were treated with drugs, fixed with 70% (v/v) ethanol
and stained with 60 g/ml propidium iodide (Sigma) con-
taining 10 U/ml ribonuclease A for 30 minutes. We mea-sured the percent of 10,000 cells in the different cell cycle
phases using the FACSCalibur™ flow cytometer built-in
ModFit LT™ 3.0 software.
Western BlotEqual amounts of protein were electrophoresed in sodium
dodecyl sulfate-polyacrylamide gel and transferred to Mil-
lipore polyvinylidene difluoride membranes (Chemicon®).
After blocking with 3% (weight per volume) nonfat dry
milk the membranes were incubated with various primary
antibodies (1:1,000) in blocking solution overnight at 4C.
Appropriate secondary antibodies (1:5,000) conjugated to
horseradish peroxidase (Pierce, Rockford, Illinois) were
incubated for 1 hour at room temperature. Immobilon™
Western ECL solution and Image Station 4000MM
HISTONE DEACETYLASE INHIBITOR POTENTIATES DOCETAXEL IN PROSTATE CANCER2558
8/8/2019 Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and…
http://slidepdf.com/reader/full/histone-deacetylase-inhibitor-potentiates-anticancer-effect-of-docetaxel-via 3/8
(Kodak, Rochester, New York) were used to visualize im-
munoreactive bands. We used antibodies to acetylated
histone 3, histone 3, caspase-3, 8 and 9, Bid, Bik, tubulin,
p21 (Cell Signaling Technology®), actin, acetylated tubu-
lin (Sigma), Bim, Mcl-1 and Bcl-xl (Santa Cruz Biotech-
nology, Santa Cruz, California).
Xenograft Animal ModelFour-week-old male BALB/C nude mice (OrientBio, Seoul,
Korea) were subcutaneously inoculated with 5 106
DU145 cells. Mice bearing tumors with a volume of about
100 mm3 intraperitoneally received docetaxel (10 or 5
mg/kg for 1 day per week at 9:00 a.m.) and PXD101 (30
mg/kg for 5 days per week at 6:00 p.m.) for 3 weeks. Tumor
volume was measured twice weekly and calculated using
the formula, tumor volume in mm3 1/2 (1 x 2
2), where
1 and 2 represent the larger and smaller tumor diame-
ters, respectively.
Statistical Analysis
All data are shown as the mean
SD. Statistical signifi-cance was considered at p0.05 and determined by 1-way
ANOVA.
RESULTS
HDAC Inhibitors
Prostate cancer cell growth inhibition. Incubating
hormone dependent LNCaP prostate cancer cells,
and DU145 and PC3 HRPC cells with 0.04, 0.2, 1, 5,
25 or 100 M SAHA or PXD101 for 48 hours de-creased cell viability in a dose dependent manner
(fig. 1, A). PXD101 was more potent than SAHA in
all preparations. DU145 cells were as sensitive as
LNCaP and more sensitive than PC3 cells (fig. 1, A).
The half maximum inhibitory concentration of
SAHA and PXD101 was 2.80 and 0.75 M in LNCaP
cells, 2.50 and 0.70 M in DU145 cells, and 6.60 and
1.20 M in PC3 cells, respectively. These results
indicate that hormone dependent and independent
prostate cancer cells are sensitive to HDACIs.
To assess the effects of these 2 HDACIs on intra-
cellular HDAC activity we analyzed histone 3 and
tubulin acetylation by Western blot in the 3 cell lines
Figure 1. Cytotoxicity and activity of HDACIs SAHA and PXD101 in LNCaP, DU145 and PC3 cell lines. A, percent viability of 4
preparations of each cell type exposed to 0.04, 0.2, 1, 5, 25 and 100 M SAHA or PXD101 for 48 hours. B , histone 3 acetylation (Ac-H3 )
was increased by HDACIs in cells exposed to 1 or 10 M SAHA or PXD101. h, hours. C , HDACIs increased acetylated tubulin (Ac-tubulin)in cells on 15% gel. Conc , concentration.
HISTONE DEACETYLASE INHIBITOR POTENTIATES DOCETAXEL IN PROSTATE CANCER 2559
8/8/2019 Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and…
http://slidepdf.com/reader/full/histone-deacetylase-inhibitor-potentiates-anticancer-effect-of-docetaxel-via 4/8
exposed to 1 or 10 M SAHA or PXD101 for the
indicated times (fig. 1, B and C). SAHA and PXD101increased histone 3 and tubulin acetylation in a time
and dose dependent manner. The histone 3 or tubu-lin level was not changed by HDACIs.
Effect on cell cycle and HRPC cell apoptotic signal- ing. To assess the effects of these HDACIs on thecell cycle we analyzed DNA contents by flow cytom-
etry. We observed an increase in the hypodiploidpopulation (sub-G1) of LNCaP, DU145 and PC3 cells
treated with 10 M SAHA or PXD101 for 48 hours(fig. 2, A and B). Exposure of these cells to 5 M
SAHA or PXD101 for 72 hours resulted in activa-tion of caspase-8, an enzyme with a role in the
extrinsic apoptotic pathway (fig. 2, C), and theactivation of caspase-9 and 3, which mediate in-
trinsic apoptosis.
Induction of DU145 cell apoptosis with doce- taxel. Since HDACI had an antiproliferative effect
on HRPC cells, we tested the effect of HDACIs ondocetaxel toxicity in DU145 cells, which are sensi-
tive to HDACIs. Although treatment with 1.5 nMdocetaxel, 1.5 M SAHA or 0.5 M PXD101 alone
resulted in modest toxicity (mean SD 69.3%
3.5%, 65.6% 7.7% and 73% 2.7% viability,
respectively), pretreatment with 1.5 nM docetaxelfollowed by 1.5 M SAHA or 0.5 M PXD101 in-
creased toxicity significantly (35.8% 8.0% and35.0% 3.6% viability, respectively, fig. 3, A).
However, administering HDACIs followed by do-cetaxel (HDACIs ¡docetaxel) had no effect on cell
death while simultaneous treatment with HDA-CIs and docetaxel was less effective than docetaxel
followed by HDACIs (fig. 3, B and C).To establish whether the combined effects of do-
cetaxel, and the HDACIs SAHA and PXD101 weresynergistic we exposed DU145 cells to the drugs
while keeping a constant ratio of each drug to theother. Growth inhibition was then measured by
MTS assay (fig. 3, D and G). Cell growth was mark-
edly inhibited by docetaxel and HDACI applied in
combination compared with that of each drug alone. Analysis of the dose effect relationship and isobolo-
grams of these results revealed that sequentialtreatment with a high concentration of docetaxel
and SAHA (docetaxel ¡SAHA) was synergistic (fig.
3, E and F ). The docetaxel and PXD101 combination(docetaxel¡PXD101) similarly showed synergy ex-cept for the highest concentration of the combination
on isobologram (fig. 3, H and I ).To investigate apoptosis induced by combination
treatment we performed flow cytometry of DU145cells sequentially exposed to docetaxel and HDACIs.
Histograms showed that combination treatment in-creased the sub-G1 population compared with cells
exposed to a single agent, that is docetaxel, SAHA or
PXD101 (fig. 3, J and K ).
Combination TreatmentApoptosis inducing mechanisms. Since pan-HDACIsand docetaxel increase in tubulin acetylation, we
examined the accumulation of tubulin acetylation in
DU145 cells using combination treatment (fig. 4, A). Although 1.5 nM docetaxel, 1.5 M SAHA or 0.5 M
PXD101 slightly increased tubulin acetylation, com-bined docetaxel/HDACIs increased it strongly. On
the other hand, adding docetaxel had no effect on thelevel of acetylation on histone 3 due to HDACIs.
Since combination treatment also significantly in-creased activated caspase-8, 9 and 3, we analyzed
the level of proteins that regulate cell survival anddeath (fig. 4, B and C). Combination treatment
decreased levels of the anti-apoptotic Bcl-2 familyproteins (Mcl-1 and Bcl-xl) and increased levels of
pro-apoptotic Bcl-2 family proteins (t-Bid, Bik andBim). This indicates that combined docetaxel and
HDACI treatment (docetaxel¡HDACIs) increasedapoptosis by modulating Bcl-2 family protein ex-
pression. The cell cycle inhibitor p21 protein wasaccumulated by combination treatment, as re-
ported previously.8
Figure 2. Apoptosis induction by SAHA or PXD101 in LNCaP, DU145 and PC3 cells. A, flow cytometry profiles show that HDACI
increased sub-G1 apoptotic population of cells treated with 10 M SAHA or PXD101 for 48 hours. B , sub-G1 population of 3 cell lines
in 3 preparations each. PXD , PXD101. Asterisk indicates p 0.05 vs control. C , Western blots of caspase-8, 9 and 3 in cells treated with5 M SAHA or PXD101 for 72 hours on 15% gel. CTL, control.
HISTONE DEACETYLASE INHIBITOR POTENTIATES DOCETAXEL IN PROSTATE CANCER2560
8/8/2019 Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and…
http://slidepdf.com/reader/full/histone-deacetylase-inhibitor-potentiates-anticancer-effect-of-docetaxel-via 5/8
Figure 3. Cytotoxicity of combined HDACI and docetaxel treatment in DU145 HRPC cells. A, 6 preparations each of cells were incubated
with 1.5 nM docetaxel (DTX ) for 24 hours and then with or without 1.5 M SAHA, or 0.5 M PXD101 for 48 hours (DTX ¡HDACI ). HDACI
posttreatment significantly potentiated docetaxel induced cell death. B , 6 preparations each of cells were incubated with 1.5 M SAHA
or 0.5 M PXD101 for 24 hours and then with or without 1.5 nM docetaxel for 48 hours (HDACI ¡ DTX ). C , 6 preparations each of cells
were exposed to HDACI, that is 1.5 M SAHA or 0.5 M PXD101, and 1.5 nM docetaxel simultaneously for 48 hours. D , viability curves
in 3 cell preparations each of single agent docetaxel and SAHA, and sequential combinations in cells treated with docetaxel and SAHA
at 1:1,000 ratio. E , CI plot of combined docetaxel and SAHA (D ). F , isobologram shows combined docetaxel and SAHA (D ). G , viability
curves of single agent docetaxel and PXD101, and sequential combinations in 3 preparations each of cells treated with docetaxel and
PXD101 at 1:333 ratio. H , CI plot of the combined docetaxel and PXD101 (G ). I , isobologram shows combined docetaxel and PXD101
(G ). J , flow cytometry profiles reveal that sub-G1 apoptotic population was greater after sequential treatment with 1.5 nM docetaxel
followed by 1.5 M SAHA or 0.5 M PXD101. CTL, control. K , bars represent sub-G1 population of sequentially (DTX ¡ HDACI ) treated
cells in 3 preparations each.
HISTONE DEACETYLASE INHIBITOR POTENTIATES DOCETAXEL IN PROSTATE CANCER 2561
8/8/2019 Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and…
http://slidepdf.com/reader/full/histone-deacetylase-inhibitor-potentiates-anticancer-effect-of-docetaxel-via 6/8
Effect on DU145 xenografts. To confirm the effectsof docetaxel and HDACI on HRPC cells in vivo we
subcutaneously injected nude mice with 5 106
DU145 cells, maintained them until the tumor size
reached 100 mm3 and then injected them intraperi-toneally with docetaxel (10 mg/kg per week) and/or
PXD101 (30 mg/kg per day) for 3 weeks. Combined
treatment reduced tumor volume compared withthat in control mice or mice treated with docetaxel orPXD101 alone but combined treatment had no effect
on body weight (fig. 5, A and B).To determine whether PXD101 decreased the re-
quired dose of docetaxel we treated tumor bearing
mice with 5 mg/kg per week docetaxel and/or 30mg/kg per day PXD101 for 3 weeks and then calcu-
lated tumor size (fig. 5, C). Injecting 5 mg/kg perweek docetaxel plus 30 mg/kg per day PXD101 re-
sulted in a mean tumor volume of 64% 0.2% thatin saline injected controls, similar to the 64% 0.3%
tumor volume in mice treated with 10 mg/kg perweek docetaxel. These results suggest that when
combined, PXD101 may allow a dose reduction of docetaxel, thus decreasing its side effects.
DISCUSSION
The finding that HDAC activity is increased in tu-
mors, including prostate cancer, led to the develop-ment of HDACIs as antitumor agents.11,23 ManyHDACIs are in phase I/II clinical trials of treatment
for hematopoietic cancer and solid tumors6 but todate only SAHA has been approved by the Food and
Drug Administration in the United States as treat-ment for cutaneous T-cell lymphoma only. We eval-
Figure 4. Western blot shows effect of sequential combination treatment with docetaxel followed by HDACI on histone acetylation,
caspase activation and Bcl-2 family protein expression in DU145 cells. A, acetylated histone 3 (Ac-H3 ) and acetylated tubulin(Ac-Tubulin) from cells incubated with 1.5 nM docetaxel for 24 hour and then next with or without 1.5 M SAHA or 0.5 M PXD101 for
48 hours on 15% gel. B , for caspase-8, 9 and 3 from cells treated with sequential combinations on 15% gel. C , Bcl-2 family proteins from
cells treated with sequential combination on 13% gel. Minuses indicate negative. Plus signs indicate positive.
Figure 5. Growth inhibitory effect of combined HDACI and docetaxel (DTX ) in DU145 xenografts in mice. A, tumor volume changes
after 3-week treatment with 10 mg/kg per week docetaxel and/or 30 mg/kg per day PXD101 ( PXD ) for 5 days per week. Asterisk indicates
p 0.05 vs control, PXD101 alone and docetaxel alone. B , total body weight in 3 treatment groups (A). C , tumor volume percent
reduction after treatment with 5 or 10 mg/kg per week docetaxel combined with 30 mg/kg per day PXD101 for 3 weeks. Minusesindicatenegative. Plus signs indicate positive. Asterisk indicates p 0.05.
HISTONE DEACETYLASE INHIBITOR POTENTIATES DOCETAXEL IN PROSTATE CANCER2562
8/8/2019 Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and…
http://slidepdf.com/reader/full/histone-deacetylase-inhibitor-potentiates-anticancer-effect-of-docetaxel-via 7/8
uated the antitumor effects of HDACIs on hormone
dependent (LNCaP) and hormone independent
(DU145 and PC3) prostate cancer cells. The pan-
HDACIs SAHA and PXD101 inhibited the growth of
hormone dependent and hormone independent cells
in a dose dependent manner (fig. 1, A). Cell cycle
analysis and Western blotting for caspase revealedthat HDACIs induced prostate cancer cell apoptosis
(fig. 2). These results suggest that pan-HDACIs may
be used for hormone dependent and independent
prostate cancer.
Since HDACIs are thought to act by potentiating
the antitumor effects of chemotherapeutic agents
and/or radiation,20,24–26 and they showed cytotoxic-
ity as monotreatment in HRPC cells in our study, we
tested whether SAHA and PXD101 could potentiate
the activity of docetaxel, an agent widely used for
HRPC. Using DU145 cells, the cell line most sensi-
tive to HDACIs of the 3 lines tested, we found thatsequential treatment with docetaxel followed by
HDACI (docetaxel ¡SAHA or PXD101) resulted in
the greatest growth inhibition (fig. 3, A). Although
HDACI cytotoxicity was lower in PC3 than in
DU145 cells, docetaxel¡HDACI combination treat-
ment had a potent antiproliferative effect in PC3
cells (data not shown). Also, median effect analysis
and isobolograms indicated that the docetaxel and
HDACI combination had synergy (fig. 3, D to I ).
These results suggest that sequential treatment
with docetaxel followed by SAHA or PXD101 may be
a useful therapy for HRPC. However, further studyis needed to elucidate the influence of the combina-
tion schedule on the response.
Docetaxel stabilizes polymerized tubulin and in-
creased tubulin acetylation is associated with such
stabilization.27 Also, HDACIs enhance tubulin acet-
ylation by inhibiting HDAC 6, an enzyme that acety-
lates cytosolic nonhistone proteins.7 In accordance
with these reports we found that the docetaxel and
HDACI combination increased the acetylated tubu-
lin level compared with that using either reagent
alone (fig. 4, A). To elucidate other mechanisms of
cell death we analyzed caspase activation and Bcl-2
family protein levels. Western blotting for caspaseshowed that combination treatment activated ex-
trinsic and intrinsic apoptosis pathways (fig. 4, B).Moreover, combination treatment increased the pro-
apoptotic proteins t-Bid, Bik and Bim, and de-
creased the anti-apoptotic proteins Mcl-1 and Bcl-xl(fig. 4, C). Depsipeptide (FK228) potentiated do-cetaxel toxicity in HRPC cells, as shown by p21
expression assays.28,29 We have extended these find-ings by noting that SAHA or PXD101 potentiated
docetaxel toxicity, and using tubulin and Bcl-2 fam-ily proteins as biomarkers in prostate cancer cell
lines.Since all of our in vitro experiments indicated
that combination treatment with docetaxel and
HDACIs has an antitumor effect on HRPC cells byinducing apoptosis, we tested the effects of combin-
ing docetaxel and PXD101 on tumor growth in nudemice injected with DU145 cells. Because it was re-
ported that combining SAH A plus docetaxel ispoorly tolerated in HRPC cases30 and PXD101 is not
a substrate of the multidrug resistance gene, wechose the combination of PXD101 plus docetaxel.
Our results show that this combination was alsoeffective in vivo against HRPC cells (fig. 5, A).
CONCLUSIONS
Results indicate that HDACI can be used to treat
patients with hormone independent and hormonedependent prostate cancer. Moreover, a sequential
combination of docetaxel and HDACIs resulted in asynergistic increase in the antiproliferative effects of
either drug given alone in DU145 HRPC cellsin vitro and in vivo. These preclinical findings sup-
port the clinical evaluation of HDACIs combinedwith docetaxel for HRPC.
ACKNOWLEDGMENTS
SAHA and PXD101 were synthesized at Crystal
Genomics, Seoul, Korea.
REFERENCES
1. Jemal A, Siegel R, Ward E et al: Cancer statis-
tics, 2009. CA Cancer J Clin 2009; 59: 225.
2. Petrylak DP, Tangen CM, Hussain MH et al:
Docetaxel and estramustine compared with mi-
toxantrone and prednisone for advanced refrac-
tory prostate cancer. N Engl J Med 2004; 351:
1513.
3. Tannock IF, de Wit R, Berry WR et al: Docetaxel
plus prednisone or mitoxantrone plus prednisonefor advanced prostate cancer. N Engl J Med
2004; 351: 1502.
4. Galsky MD and Vogelzang NJ: Docetaxel-based
combination therapy for castration-resistant pros-
tate cancer. Ann Oncol 2010; Epub ahead of print.
5. Johnstone RW and Licht JD: Histone deacetylase
inhibitors in cancer therapy: is transcription the
primary target? Cancer Cell 2003; 4: 13.
6. Acharya MR, Sparreboom A, Venitz J et al: Ra-
tional development of histone deacetylase inhib-
itors as anticancer agents: a review. Mol Phar-
macol 2005; 68: 917.
7. Minucci S and Pelicci PG: Histone deacetylase
inhibitors and the promise of epigenetic (and
more) treatments for cancer. Nat Rev Cancer
2006; 6: 38.
8. Xu WS, Parmigiani RB and Marks PA: Histone
deacetylase inhibitors: molecular mechanisms of
action. Oncogene 2007; 26: 5541.
9. Glaser KB: HDAC inhibitors: clinical update and
mechanism-based potential. Biochem Pharmacol
2007; 74: 659.
HISTONE DEACETYLASE INHIBITOR POTENTIATES DOCETAXEL IN PROSTATE CANCER 2563
8/8/2019 Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and…
http://slidepdf.com/reader/full/histone-deacetylase-inhibitor-potentiates-anticancer-effect-of-docetaxel-via 8/8
10. Mai A, Massa S, Rotili D et al: Histone deacety-
lation in epigenetics: an attractive target for an-
ticancer therapy. Med Res Rev 2005; 25: 261.
11. Abbas A and Gupta S: The role of histone
deacetylases in prostate cancer. Epigenetics
2008; 3: 300.
12. Insinga A, Monestiroli S, Ronzoni S et al: Inhib-
itors of histone deacetylases induce tumor-selec-
tive apoptosis through activation of the death
receptor pathway. Nat Med 2005; 11: 71.
13. Haggarty SJ, Koeller KM, Wong JC et al: Do-
main-selective small-molecule inhibitor of his-
tone deacetylase 6 (HDAC6)-mediated tubulin
deacetylation. Proc Natl Acad Sci U S A 2003;
100: 4389.
14. Bali P, Pranpat M, Bradner J et al: Inhibition of
histone deacetylase 6 acetylates and disrupts the
chaperone function of heat shock protein 90: a
novel basis for antileukemia activity of histonedeacetylase inhibitors. J Biol Chem 2005; 280:
26729.
15. Subramanian C, Opipari AW Jr, Bian X et al: Ku70
acetylation mediates neuroblastoma cell death
induced by histone deacetylase inhibitors. Proc
Natl Acad Sci U S A 2005; 102: 4842.
16. Thelen P, Schweyer S, Hemmerlein B et al: Ex-
pressional changes after histone deacetylase in-
hibition by valproic acid in LNCaP human prostate
cancer cells. Int J Oncol 2004; 24: 25.
17. Qian DZ, Wei YF, Wang X et al: Antitumor activity
of the histone deacetylase inhibitor MS-275 in
prostate cancer models. Prostate 2007; 67: 1182.
18. Qian X, Ara G, Mills E et al: Activity of the histone
deacetylase inhibitor belinostat (PXD101) in pre-
clinical models of prostate cancer. Int J Cancer
2008; 122: 1400.
19. D’Acunto CW, Fontanella B, Rodriquez M et al:
Histone deacetylase inhibitor FR235222 sensi-
tizes human prostate adenocarcinoma cells to
apoptosis through up-regulation of Annexin A1.
Cancer Lett 2010; 295: 85.
20. Rathkopf D, Wong BY, Ross RW et al: A phase I
study of oral panobinostat alone and in combina-
tion with docetaxel in patients with castration-
resistant prostate cancer. Cancer Chemother
Pharmacol 2010; 66: 181.
21. Daugaard G, Fizazi K, Huebner G et al: An open-
label randomized phase II trial of belinostat
(PXD101) in combination with carboplatin andpaclitaxel (BelCaP) compared to carboplatin and
paclitaxel in patients with previously untreated
carcinoma of unknown primary. J Clin Oncol,
suppl., 2010; 28: 15s, abstract TPS185.
22. Reid T, Thorne S, Hedjran F et al: Impact of the
histone deacetylase inhibitors on taxotere resis-
tance due to P-gp (MDR) and tubulin acetylation.
Proc Amer Assoc Cancer Res 2005; 46.
23. Di Croce L, Buschbeck M, Gutierrez A et al:
Altered epigenetic signals in human disease.
Cancer Biol Ther 2004; 3: 831.
24. Di Lorenzo G, Figg WD, Fossa SD et al: Combi-
nation of bevacizumab and docetaxel in do-
cetaxel-pretreated hormone-refractory prostate
cancer: a phase 2 study. Eur Urol 2008; 54: 1089.
25. Kim MS, Blake M, Baek JH et al: Inhibition of
histone deacetylase increases cytotoxicity to an-
ticancer drugs targeting DNA. Cancer Res 2003;63: 7291.
26. Chen Y, Sawyers CL and Scher HI: Targeting the
androgen receptor pathway in prostate cancer.
Curr Opin Pharmacol 2008; 8: 440.
27. Piperno G, LeDizet M and Chang XJ: Microtu-
bules containing acetylated alpha-tubulin in
mammalian cells in culture. J Cell Biol 1987; 104:
289.
28. Zhang Z, Stanfield J, Frenkel E et al: Enhanced
therapeutic effect on androgen-independent pros-
tate cancer by depsipeptide (FK228), a histone
deacetylase inhibitor, in combination with do-cetaxel. Urology 2007; 70: 396.
29. Kanzaki M, Kakinuma H, Kumazawa T et al: Low
concentrations of the histone deacetylase inhib-
itor, depsipeptide, enhance the effects of gem-
citabine and docetaxel in hormone refractory
prostate cancer cells. Oncol Rep 2007; 17: 761.
30. Schneider BJ, Bradley D, Smith DC et al: Phase I
study of vorinostat plus docetaxel in patients
with solid tumor malignancies. J Clin Oncol,
suppl., 2009; 27: 15s, abstract 2528.
HISTONE DEACETYLASE INHIBITOR POTENTIATES DOCETAXEL IN PROSTATE CANCER2564